The degree of complexity and crossover within MAPK signaling, and also shifts in pathways such as nuclear factor κB signaling, could also explain the modest effect of p38 inhibitors. The p38α ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American ...

Patients with MAPK pathway driven advanced solid tumors and specific mutations or those who have failed prior treatments can participate. Disclaimer: This is an AI-generated summary of a press ...